Literature DB >> 25511890

Demyelinating disease: Is TOPIC the last trial for clinically isolated syndrome?

Bruce A C Cree1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25511890     DOI： 10.1038/nrneurol.2014.239

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors:  L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

2.  Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

Authors:  Giancarlo Comi; Nicola De Stefano; Mark S Freedman; Frederik Barkhof; Chris H Polman; Bernard M J Uitdehaag; Florence Casset-Semanaz; Brian Hennessy; Margaretha Stam Moraga; Sanda Rocak; Bettina Stubinski; Ludwig Kappos
Journal:  Lancet Neurol       Date:  2011-12-04       Impact factor: 44.182

3.  Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.

Authors:  Thomas P Leist; Giancarlo Comi; Bruce A C Cree; Patricia K Coyle; Mark S Freedman; Hans-Peter Hartung; Patrick Vermersch; Florence Casset-Semanaz; Matthew Scaramozza
Journal:  Lancet Neurol       Date:  2014-02-04       Impact factor: 44.182

4.  MRI criteria for MS in patients with clinically isolated syndromes.

Authors:  X Montalban; M Tintoré; J Swanton; F Barkhof; F Fazekas; M Filippi; J Frederiksen; L Kappos; J Palace; C Polman; M Rovaris; N de Stefano; A Thompson; T Yousry; A Rovira; D H Miller
Journal:  Neurology       Date:  2010-01-06       Impact factor: 9.910

5.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.

Authors:  L K Fisniku; P A Brex; D R Altmann; K A Miszkiel; C E Benton; R Lanyon; A J Thompson; D H Miller
Journal:  Brain       Date:  2008-01-29       Impact factor: 13.501

6.  The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study.

Authors:  S P Morrissey; D H Miller; B E Kendall; D P Kingsley; M A Kelly; D A Francis; D G MacManus; W I McDonald
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

7.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Authors:  G Comi; V Martinelli; M Rodegher; L Moiola; O Bajenaru; A Carra; I Elovaara; F Fazekas; H P Hartung; J Hillert; J King; S Komoly; C Lubetzki; X Montalban; K M Myhr; M Ravnborg; P Rieckmann; D Wynn; C Young; M Filippi
Journal:  Lancet       Date:  2009-10-06       Impact factor: 79.321

8.  Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Aaron E Miller; Jerry S Wolinsky; Ludwig Kappos; Giancarlo Comi; Mark S Freedman; Tomas P Olsson; Deborah Bauer; Myriam Benamor; Philippe Truffinet; Paul W O'Connor
Journal:  Lancet Neurol       Date:  2014-09-02       Impact factor: 44.182

9.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.

Authors:  Peter A Brex; Olga Ciccarelli; Jonathon I O'Riordan; Michael Sailer; Alan J Thompson; David H Miller
Journal:  N Engl J Med       Date:  2002-01-17       Impact factor: 91.245

10.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

Authors:  L Kappos; C H Polman; M S Freedman; G Edan; H P Hartung; D H Miller; X Montalban; F Barkhof; L Bauer; P Jakobs; C Pohl; R Sandbrink
Journal:  Neurology       Date:  2006-08-16       Impact factor: 9.910
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.